Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.54 |
| ▸ | BID | P55957 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.50 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28193718 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL31079007 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003626 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1002751 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1002777 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL421013 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1004461 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL5566506 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003944 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003237 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002541249-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1171432-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | claimed |
| WO-2000061569-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | claimed |
| US-8778219-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8535560-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2011008664-A2 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | UT-BATTELLE, LLC (US) | 2011-01-20 | — | — | US | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| EP-1171432-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000061569-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | POU2F1, POU2F2, POF1B | LMNA 4185/4885MEN1 1717/4885NR1I2 1669/4885 |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | POU2F1, POU2F2, POF1B | LMNA 4185/4885MEN1 1717/4885NR1I2 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.